ExpandMost Patient Health Questionnaire-9 (PHQ-9) responses, which are primarily patient entered, were submitted during the day; submission volumes peaked mid-morning and were lowest overnight, with only about 2.5% of submissions between 11 p.m. and 5:59 a.m.
ExpandMost Patient Health Questionnaire-9 (PHQ-9) responses, which are primarily patient entered, were submitted during the day; submission volumes peaked mid-morning and were lowest overnight, with only about 2.5% of submissions between 11 p.m. and 5:59 a.m.
ExpandAmong adults without diabetes who lost weight during their first year on a GLP-1 medication, most sustained that loss into the second year. At the two-year mark, 53.1% of semaglutide patients and 52.9% of tirzepatide patients had maintained their weight within a narrow band of their one-year weight, and a further 31.9% (semaglutide) and 39.3% (tirzepatide) had lost even more.
ExpandAmong adults with diabetes who lost weight during their first year on a GLP-1 medication, most maintained or extended that loss when the GLP-1 was continued into the second year. At the two-year mark, 37.7% of semaglutide patients and 47.3% of tirzepatide patients had maintained their weight loss, and another 35.4% and 38.6%, respectively, had continued to lose weight.
ExpandAmong patients newly diagnosed with Parkinson’s disease, 90.2% were aged 60 or older at diagnosis, with a median diagnosis age of 73. Diagnoses before age 50 were rare, accounting for 2.6% of patients.
ExpandAmong patients newly diagnosed with Parkinson’s disease, 90.2% were aged 60 or older at diagnosis, with a median diagnosis age of 73. Diagnoses before age 50 were rare, accounting for 2.6% of patients.
ExpandUnder the 2026 cholesterol treatment guideline, 54.6% of adults aged 20–79 without established cardiovascular disease were eligible for lipid-lowering therapy, compared with 41.3% under the 2018 guideline, a 13.3 percentage-point increase in the treatment-eligible share.
ExpandUnder the 2026 cholesterol treatment guideline, 54.6% of adults aged 20–79 without established cardiovascular disease were eligible for lipid-lowering therapy, compared with 41.3% under the 2018 guideline, a 13.3 percentage-point increase in the treatment-eligible share.
ExpandAmong women seen in outpatient care, the rate of hormone therapy (HT) use rose from 1.7% in January 2017 to 3.6% in April 2026, a near-doubling. The increase was modest through 2022 and then accelerated sharply from 2023 onward.
ExpandAmong women seen in outpatient care, the rate of hormone therapy (HT) use rose from 1.7% in January 2017 to 3.6% in April 2026, a near-doubling. The increase was modest through 2022 and then accelerated sharply from 2023 onward.
ExpandThe share of male patients prescribed testosterone fell from 0.83% in 2013 to 0.64% by 2021. It then rose to 0.93% in 2025 and reached 0.95% in the partial first half of 2026.
ExpandThe share of male patients prescribed testosterone fell from 0.83% in 2013 to 0.64% by 2021. It then rose to 0.93% in 2025 and reached 0.95% in the partial first half of 2026.
ExpandMale patients aged 10 to 15 who had an ED visit for a motor vehicle crash (MVC) were as much as four times as likely to experience a subsequent firearm injury compared with those whose ED visit was for a fall, in some parts of the United States.
ExpandThe risks of myocardial infarction (MI), ischemic stroke, and hemorrhagic stroke are increased for patients with high or low average systolic blood pressure (BP). The risks are greater at very low systolic BP than at very high systolic BP.
ExpandAt 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight.
ExpandMale patients aged 10 to 15 who had an ED visit for a motor vehicle crash (MVC) were as much as four times as likely to experience a subsequent firearm injury compared with those whose ED visit was for a fall, in some parts of the United States.
ExpandThe risks of myocardial infarction (MI), ischemic stroke, and hemorrhagic stroke are increased for patients with high or low average systolic blood pressure (BP). The risks are greater at very low systolic BP than at very high systolic BP.
ExpandAt 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight.
ExpandAmong patients newly eligible for cancer screening, those diagnosed with autism had a 35.6% lower likelihood of on-time screening overall compared to patients without autism. The gap was largest for cervical (50.7% lower likelihood) and breast (28.7% lower likelihood) cancer screening, and smaller but still significant for prostate cancer screening (14.9% lower likelihood).
ExpandMale patients aged 10 to 15 who had an ED visit for a motor vehicle crash (MVC) were as much as four times as likely to experience a subsequent firearm injury compared with those whose ED visit was for a fall, in some parts of the United States.
ExpandThe risks of myocardial infarction (MI), ischemic stroke, and hemorrhagic stroke are increased for patients with high or low average systolic blood pressure (BP). The risks are greater at very low systolic BP than at very high systolic BP.
ExpandAt 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight.
